AHA Scientific Sessions 2026 Abstract·Nov 7Comparative Cardiovascular Outcomes Across PCSK9-Targeted Therapies: A Real-World Matched Cohort Analysis of Inclisiran, Alirocumab, and EvolocumabCohort study in peopleAlirocumabPaper
ESC Congress 2026 Abstract·Oct 26Achievement of secondary prevention targets after STEMI: results from the IMPACS StudyStudy of 1,031 peopleInterventionsPaper
ESC Congress 2026 Abstract·Oct 26Perceived effectiveness of PCSK9i-SiRNA therapy and adherence to background statin therapy: real-world analysis of the DAMAGE registryCohort study of 403 peopleStatinsPaper
The American Journal of Medicine·Aug 9Association between PCSK9 targeted therapy and the risk of stroke and dementia: A meta-analysis of randomized controlled trialsMeta-analysis of randomized trialsDementiaPaper